Clinical trial NCT06610136: Caffeine and Resistance Training in Young Adults
Official title: Effects of Acute and Prolonged Caffeine Intake on Neuromuscular Adaptations to Resistance Training in Young Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Caffeine and Resistance Training
Lead sponsor: University of Alcala
Sponsor class: OTHER
First posted: 2024-09-24
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized controlled trial
Primary purpose: OTHER

Brief summary: Introduction: Several studies have evaluated and confirmed the ergogenic effect of acute caffeine intake on sports performance, specifically on strength and power performance. However, little is known about the prolonged effect of this supplement on neuromuscular adaptations to strength training.

Introduction: Several studies have evaluated and confirmed the ergogenic effect of acute caffeine intake on sports performance, specifically on strength and power performance. However, little is known about the prolonged effects of this supplement on neuromuscular adaptations to strength training.

Objectives: The present study aims to analyze the effects of acute and chronic caffeine intake on neuromuscular adaptations to strength training, according to sex (men vs. women) and type of exercise (bench press vs. squat), as well as on fatigue resistance during repeated sprints, fatigue perception, mood state, reaction time, diet, and potential side effects.


Eligibility criteria: Inclusion Criteria:

* Age between ≥ 18 and ≤ 35 years.
* Body mass index (BMI) \&lt; 25 kg/m².
* Physically active subjects (\&gt;150 min/week of moderate exercise).
* Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise.
* Participants capable of performing the tests.

Exclusion Criteria:

* History of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism.
* Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study.
* Body mass index (BMI) \&gt; 25 kg/m².
* Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study.
* Performing strenuous exercise within 48 hours prior to the tests.
* Failing to replicate the same food intake on the two experimental days.
* Consuming caffeine after 6 PM on the day prior to training or testing.

Primary outcomes:
measure: Mean velocity at different %1RM
timeFrame: Through study completion, an average of 12 weeks
measure: Peak velocity at different %1RM
timeFrame: Through study completion, an average of 12 weeks
measure: Mean power output at different %1RM
timeFrame: Through study completion, an average of 12 weeks
measure: Peak power output and time to reach peak power output at different %1RM
timeFrame: Through study completion, an average of 12 weeks
measure: Number of repetitions performed at 65%1RM until task failure
timeFrame: Through study completion, an average of 12 weeks
measure: Bar velocity deplacement performed in 1 set at 65%1RM until task failure
timeFrame: Through study completion, an average of 12 weeks
measure: Power output generated in 1 set at 65%1RM until task failure
timeFrame: Through study completion, an average of 12 weeks
Secondary outcomes:
measure: Resting Metabolic Rate (RMR)
timeFrame: Through study completion, an average of 12 weeks
measure: Maximal Fat Oxidation Rate (MFO)
timeFrame: Through study completion, an average of 12 weeks
measure: Fat mass
timeFrame: Through study completion, an average of 12 weeks
measure: Fat-free mass
timeFrame: Through study completion, an average of 12 weeks
measure: Physical activity (METs-min/wk)
timeFrame: Through study completion, an average of 12 weeks
measure: Dietary (g/kg of macronutrients)
timeFrame: Through study completion, an average of 12 weeks
measure: Mood state
timeFrame: Through study completion, an average of 12 weeks
measure: Adverse effects
timeFrame: Through study completion, an average of 12 weeks
Other outcomes:
Locations:
city: Alcalá de Henares
country: Spain
facility: Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
state: Madrid
Study officials:
References: